U.S. Markets close in 1 hr 35 mins
  • S&P 500

    4,241.53
    +16.74 (+0.40%)
     
  • Dow 30

    33,931.68
    +54.71 (+0.16%)
     
  • Nasdaq

    14,212.02
    +70.54 (+0.50%)
     
  • Russell 2000

    2,282.95
    -3.14 (-0.14%)
     
  • Crude Oil

    73.11
    -0.55 (-0.75%)
     
  • Gold

    1,778.40
    -4.50 (-0.25%)
     
  • Silver

    25.85
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1943
    +0.0019 (+0.1553%)
     
  • 10-Yr Bond

    1.4780
    -0.0060 (-0.40%)
     
  • Vix

    17.20
    -0.69 (-3.86%)
     
  • GBP/USD

    1.3941
    +0.0008 (+0.0558%)
     
  • USD/JPY

    110.6580
    +0.3600 (+0.3264%)
     
  • BTC-USD

    32,589.29
    +120.39 (+0.37%)
     
  • CMC Crypto 200

    775.03
    -19.30 (-2.43%)
     
  • FTSE 100

    7,090.01
    +27.72 (+0.39%)
     
  • Nikkei 225

    28,884.13
    +873.20 (+3.12%)
     

SELLAS Life Sciences to Host Shareholder Update Call on June 3rd

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that it will host a Shareholder Update Call on Thursday, June 3, 2021 at 8:30 a.m. ET.

The call will be facilitated by SELLAS’ President & CEO, Angelos Stergiou, MD, ScD. h.c., who will provide a corporate update.

Event:

Shareholder Update Call

Date:

Thursday, June 3, 2021

Time:

8:30 a.m. ET

Live Call:

1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)

Webcast:

https://www.sellaslifesciences.com/investors/events-and-presentations

For interested individuals unable to join the conference call, a replay of the call will be available through June 17, 2021, at 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13719788. The online archive of the webcast will be available at https://www.sellaslifesciences.com/investors/events-and-presentations after the conclusion of the call.

About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following the standard of care.

For more information on SELLAS, please visit www.sellaslifesciences.com.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various important factors. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

For more information, please contact:

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 914.907.2675 / 215.272.2707

Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 212.896.1241 / 212.896.1276